REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
440.94
+1.57 (+0.36%)
At close: 4:00PM EDT

436.35 -4.59 (-1.04%)
After hours: 7:34PM EDT

Stock chart is not supported by your current browser
Previous Close439.37
Open439.59
Bid365.34 x 100
Ask443.88 x 200
Day's Range438.00 - 443.00
52 Week Range325.35 - 543.55
Volume639,318
Avg. Volume742,141
Market Cap47B
Beta1.66
PE Ratio (TTM)44.24
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug
    Zacks2 days ago

    Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug

    Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.

  • Reuters2 days ago

    Regeneron-Sanofi drug succeeds mid-stage study

    The drug, dupilumab, was statistically significant in improving the ability to swallow in adults with moderate-to-severe eosinophilic esophagitis, when compared with a placebo. Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the pipe that connects the throat and the stomach, and can lead to food getting stuck in the oesophagus and difficulties in swallowing.

  • Sanofi/Regeneron's Dupixent Succeeds in Phase II Study
    Zacks2 days ago

    Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

    Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.

  • Market Realist3 days ago

    Gilead Sciences on the Street: Analyst Recommendations in October

    Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."

  • Reuters3 days ago

    UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study

    Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study. The drug, dupilumab, was statistically significant in improving the ability to swallow in adults with moderate-to-severe eosinophilic esophagitis, when compared with a placebo. Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the pipe that connects the throat and the stomach, and can lead to food getting stuck in the esophagus and difficulties in swallowing.

  • Reuters3 days ago

    Aimmune teams with Regeneron, Sanofi on peanut allergy drug

    Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug. The company said it would test the drug, AR101, in combination with Regeneron and Sanofi's dupilumab in a mid-stage trial that is expected to start in 2018 and will be sponsored by Regeneron. AR101, an oral immunotherapy, is already being tested as a mono-therapy for peanut allergy in a late-stage trial.

  • Reuters4 days ago

    Regeneron-Sanofi throat infection drug succeeds key study

    Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat patients with a rare throat infection met the main goal of a mid-stage study. The drug, dupilumab, was statistically significant ...

  • 6 Top Biotech Companies In Innovation Earn Recognition In New Awards
    Investor's Business Daily4 days ago

    6 Top Biotech Companies In Innovation Earn Recognition In New Awards

    Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?

  • Regeneron Advances Science To Attack Arthritis, Eye Disease, More
    Investor's Business Daily4 days ago

    Regeneron Advances Science To Attack Arthritis, Eye Disease, More

    Regeneron became a star with its treatment for a common eye disease, but treatments for dermatitis, arthritis, asthma and cancer could bring superstardom.

  • Market Realist4 days ago

    Dupixent May Be Strong Growth Driver for Sanofi in the Future

    Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).

  • Drugmakers Are Planning to Start a Phase 2 Trial to Cure Peanut Allergy
    Bloomberg4 days ago

    Drugmakers Are Planning to Start a Phase 2 Trial to Cure Peanut Allergy

    Aimmune Therapeutics Inc. is teaming with Regeneron Pharmaceuticals Inc. in hopes of developing a cure for peanut allergies.

  • Dow's Merck Bails On Cholesterol Drug, Prodding Shares Down
    Investor's Business Daily8 days ago

    Dow's Merck Bails On Cholesterol Drug, Prodding Shares Down

    Dow component Merck said late Wednesday it won't submit applications for approval of a cholesterol drug.

  • Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
    Zacks9 days ago

    Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

    With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

  • This Biotech Hit Record High; Could Undercut Regeneron In Eczema
    Investor's Business Daily9 days ago

    This Biotech Hit Record High; Could Undercut Regeneron In Eczema

    AnaptysBio soared Tuesday after its eczema drug appeared to outperform a potential blockbuster rival drug from Regeneron and Sanofi.

  • Barrons.com10 days ago

    [$$] Ruling Goes Regeneron's Way

    Gabelli & Co. We reiterate a Buy rating on Regeneron Pharmaceuticals with an estimated 2018 private market value of $554 a share. On Oct. 5, Regeneron (REGN) announced that the appeals court has removed the permanent injunction on Praluent. The injunction was issued in January to block sales of Praluent, after a federal jury ruled against Regeneron in patent litigation and declared two of Amgen’s (AMGN) patents linked to PCSK9 in March 2016 valid.

  • Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : October 9, 2017
    Capital Cube11 days ago

    Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : October 9, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Regeneron Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Why Regeneron's Patent Win Is Worse For Amgen Than You Think
    Investor's Business Daily13 days ago

    Why Regeneron's Patent Win Is Worse For Amgen Than You Think

    Amgen's patents covering LDL cholesterol-lowering drug Repatha are likely to be invalidated, an analyst says.

  • Regeneron and Sanofi Get Favorable Ruling Against Amgen
    Zacks13 days ago

    Regeneron and Sanofi Get Favorable Ruling Against Amgen

    Regeneron Pharmaceuticals(REGN) and partner Sanofi, Inc. (SNY) receives a favorable ruling from the Court of Appeals for the Federal Circuit relating to Praluent.

  • Regeneron Pops After Judge Tosses Ban On Amgen-Rivaling Med
    Investor's Business Daily14 days ago

    Regeneron Pops After Judge Tosses Ban On Amgen-Rivaling Med

    Regeneron shares climbed after a court tossed out a ban on sales of Regeneron and Sanofi's Praluent.

  • The Wall Street Journal14 days ago

    [$$] Appeals Court Rules Against Amgen in Patent Case

    A U.S. federal appeals court said Regeneron Pharmaceuticals and partner Sanofi can continue selling their cholesterol drug, dealing a blow to rival Amgen, which had accused the companies of violating its ...

  • Reuters14 days ago

    U.S. court reverses ban on sale of Regeneron, Sanofi cholesterol drug

    A U.S. appeals court on Thursday threw out a ban on the sale of Regeneron Pharmaceuticals Inc and Sanofi SA's cholesterol-lowering drug Praluent, and ordered a new trial after finding a jury was given improper instructions. The ruling from the U.S. Court of Appeals for the Federal Circuit in Washington was a setback for Amgen Inc, which claimed Praluent infringed patents on its rival drug, Repatha, and had won the sales ban after a jury trial.

  • Barrons.com14 days ago

    Why Amgen is Sliding

    Shares of Amgen (AMGN) are sliding this morning after a judge ruled that Regeneron Pharmaceuticals' (REGN) Praluent can stay on the market for the time being. The ruling was made in an ongoing patent battle between Amgen and Regeneron and its partner Sanofi (SNY). The Court is allowing for REGN's Praluent to stay on the market for the time being on the basis the that earlier proceeding in district court was conducted in error.

  • Pres Trump believes he has the cure for Obamacare
    Yahoo Finance Video7 days ago

    Pres Trump believes he has the cure for Obamacare

    President Trump's healthcare bill may have died in Congress, but that's not stopping him from making changes to Obamacare. Later today, the president is expected to sign an executive order that would let Americans buy insurance across state lines. Yahoo Finance’s Alexis Christoforous and Editor-in-Chief Andy Serwer figure out if the the president’s move will help lower premiums.

  • Regeneron spiking on court ruling vs. Amgen
    CNBC Videos14 days ago

    Regeneron spiking on court ruling vs. Amgen

    CNBC's Seema Mody reports on Regeneron resuming trade and spiking after winning a court ruling against Amgen.

  • Regeneron shares pop on cholesterol drug approval
    CNBC Videos14 days ago

    Regeneron shares pop on cholesterol drug approval

    Regeneron shares are popping intraday after news of their cholesterol drug receives approval.